{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:19:34Z","timestamp":1789726774290,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009342","name":"Aeras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2017.01.055","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T08:30:43Z","timestamp":1487320243000},"page":"1652-1661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials"],"prefix":"10.1016","volume":"35","author":[{"given":"Maria","family":"Norrby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Vesikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Maeurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raija","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Mahdavifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bruce","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daner","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hokey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Kromann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren T.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00ebtte W.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H.M.","family":"Ottenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Brighenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.01.055_b0005","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.2223\/JPED.1499","article-title":"BCG vaccine: efficacy and indications for vaccination and revaccination","volume":"82","author":"Barreto","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2017.01.055_b0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.01.055_b0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-3083.1992.tb03104.x","article-title":"A family of cross-reacting proteins secreted by Mycobacterium tuberculosis","volume":"36","author":"Wiker","year":"1992","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.055_b0020","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1126\/science.276.5317.1420","article-title":"Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis","volume":"276","author":"Belisle","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.01.055_b0025","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model","volume":"97","author":"Horwitz","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.01.055_b0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/IAI.68.1.214-220.2000","article-title":"Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens","volume":"68","author":"Skjot","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.055_b0035","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1128\/IAI.70.10.5446-5453.2002","article-title":"Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family","volume":"70","author":"Skjot","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.055_b0040","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.4049\/jimmunol.174.10.6332","article-title":"Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy","volume":"174","author":"Dietrich","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.055_b0045","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0050","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"van Dissel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-065X.2008.00693.x","article-title":"Early T-cell responses in tuberculosis immunity","volume":"225","author":"Winslow","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2017.01.055_b0060","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31","volume":"24","author":"Agger","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0065","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1016\/j.vaccine.2006.03.071","article-title":"IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses","volume":"24","author":"Schellack","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0070","doi-asserted-by":"crossref","first-page":"e39909","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","author":"Billeskov","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0075","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","article-title":"Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen","volume":"28","author":"Skeiky","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0080","doi-asserted-by":"crossref","first-page":"e5930","DOI":"10.1371\/journal.pone.0005930","article-title":"Protection and polyfunctional T cells induced by Ag85B-TB10.4\/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose","volume":"4","author":"Aagaard","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0085","unstructured":"Food and Drug Administration (FDA) USDoHHS. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials; September, 2007."},{"key":"10.1016\/j.vaccine.2017.01.055_b0090","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0095","doi-asserted-by":"crossref","first-page":"e7972","DOI":"10.1371\/journal.pone.0007972","article-title":"Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis","volume":"4","author":"Smith","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2011.05.008","article-title":"Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection","volume":"370","author":"Borgstrom","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.01.055_b0105","doi-asserted-by":"crossref","first-page":"e3790","DOI":"10.1371\/journal.pone.0003790","article-title":"rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector","volume":"3","author":"Magalhaes","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0110","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.055_b0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tube.2012.10.011","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02 in PPD positive adults: a randomized controlled phase I\/II study","volume":"93","author":"Spertini","year":"2013","journal-title":"Tuberculosis"},{"key":"10.1016\/j.vaccine.2017.01.055_b0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.01.055_b0125","doi-asserted-by":"crossref","first-page":"e1002607","DOI":"10.1371\/journal.ppat.1002607","article-title":"Vaccines against tuberculosis: where are we and where do we need to go?","volume":"8","author":"Ottenhoff","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.01.055_b0130","doi-asserted-by":"crossref","first-page":"e40882","DOI":"10.1371\/journal.pone.0040882","article-title":"Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach","volume":"7","author":"Davila","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0135","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1128\/IAI.02086-05","article-title":"High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection","volume":"74","author":"Hervas-Stubbs","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.055_b0140","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.01.055_b0145","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.01.055_b0150","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.4049\/jimmunol.181.7.4955","article-title":"Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice","volume":"181","author":"Forbes","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.055_b0155","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","article-title":"Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells","volume":"182","author":"Lindenstrom","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.055_b0160","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/CVI.00133-10","article-title":"Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F\/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults","volume":"17","author":"Leroux-Roels","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.01.055_b0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2010.02.141","article-title":"Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection","volume":"396","author":"Brighenti","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2017.01.055_b0170","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/blood-2002-04-1136","article-title":"CD8alpha alpha memory effector T cells descend directly from clonally expanded CD8alpha +beta high TCRalpha beta T cells in vivo","volume":"100","author":"Konno","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.01.055_b0175","doi-asserted-by":"crossref","first-page":"e3683","DOI":"10.1371\/journal.pone.0003683","article-title":"Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant","volume":"3","author":"Kamath","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0180","doi-asserted-by":"crossref","first-page":"e55264","DOI":"10.1371\/journal.pone.0055264","article-title":"The two-component adjuvant IC31(R) boosts type 1 interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs","volume":"8","author":"Szabo","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.01.055_b0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/vaccines4020014","article-title":"Effects of KLK peptide on adjuvanticity of different ODN sequences","volume":"4","author":"Chikh","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2017.01.055_b0190","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2119\/molmed.2011.00222","article-title":"Prime-boost vaccination with rBCG\/rAd35 enhances CD8(+) cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates","volume":"18","author":"Rahman","year":"2012","journal-title":"Mol Med"},{"key":"10.1016\/j.vaccine.2017.01.055_b0195","doi-asserted-by":"crossref","first-page":"e00679","DOI":"10.1128\/mBio.00679-16","article-title":"Deletion of nuoG from the vaccine candidate Mycobacterium bovis BCG DeltaureC::hly improves protection against tuberculosis","volume":"7","author":"Gengenbacher","year":"2016","journal-title":"MBio"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17301202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17301202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T06:59:54Z","timestamp":1658645994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17301202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X17301202"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}